Details of the Drug

General Information of Drug (ID: DML6CN4)

Drug Name
Acemetacin
Synonyms
Acemetacina; Acemetacina [INN-Spanish]; Acemetacine; Acemetacine [INN-French]; Acemetacinum; Acemetacinum [INN-Latin]; Acemix; Aximeixin; Emflex; Rantudil; Rheumibis; TVX 3322; indometacin carboxymethyl ester; indometacin glycolic ester; indomethacin carboxymethyl ester; indomethacin glycolic ester; 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester; 53164-05-9; BRN 0501672; Bay f 4975; C21H18ClNO6; CHEBI:31162; CHEMBL189171; EINECS 258-403-4; K 708; K-708; UNII-5V141XK28X; acemetacin
Affected Organisms
Humans and other mammals
ATC Code
M01AB11: Acemetacin
M01AB: Acetic acid derivatives and related substances
M01A: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M: MUSCULO-SKELETAL SYSTEM
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 415.8
Logarithm of the Partition Coefficient (xlogp) 4.2
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 483-712 mcgh/L [1]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 276.8 mcg/L [1]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2.5 h [1]
Clearance
The clearance of drug is 4.59 mL/min/kg [2]
Elimination
The elimination of acemetacin is divided in renal elimination that covers 40% of the complete administered dose and the restant 60% is excreted in feces []
Half-life
The concentration or amount of drug in body reduced by one-half in 4.5 hours [3]
Metabolism
The drug is metabolized via the esterolytic cleavage to form its major and active metabolite indometacin []
Vd
The volume of distribution (Vd) of drug is 0.5-0.7 L/kg []
Chemical Identifiers
Formula
C21H18ClNO6
IUPAC Name
2-[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]oxyacetic acid
Canonical SMILES
CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(=O)O
InChI
FSQKKOOTNAMONP-UHFFFAOYSA-N
InChIKey
1S/C21H18ClNO6/c1-12-16(10-20(26)29-11-19(24)25)17-9-15(28-2)7-8-18(17)23(12)21(27)13-3-5-14(22)6-4-13/h3-9H,10-11H2,1-2H3,(H,24,25)
Cross-matching ID
PubChem CID
1981
ChEBI ID
CHEBI:31162
CAS Number
53164-05-9
UNII
5V141XK28X
DrugBank ID
DB13783
INTEDE ID
DR0035
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
UDP-glucuronosyltransferase 2B7 (UGT2B7)
Main DME 		DEB3CV1 UD2B7_HUMAN Substrate [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Jones RW, Collins AJ, Notarianni LJ, Sedman E: The comparative pharmacokinetics of acemetacin in young subjects and elderly patients. Br J Clin Pharmacol. 1991 May;31(5):543-5.
2 Ochs HR, Schuppan U, Greenblatt DJ, Abernethy DR: Reduced distribution and clearance of acetaminophen in patients with congestive heart failure. J Cardiovasc Pharmacol. 1983 Jul-Aug;5(4):697-9.
3 [Metabolism and pharmacokinetics of acemetacin in man (author's transl)]. Arzneimittelforschung. 1980;30(8A):1391-8.
4 Seyffart G. (1992). Drug dosage in renal insufficiency (2nd ed.). Springer Science+Business Media Dordrecht.